Serum IL-17A in Behçet’s disease

Nazan Emiroglu; Fatma Pelin Cengiz; Gul Bahar Erdem

doi:10.5114/pdia.2015.54745

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2015
vol. 32

Send email

Copy url:

abstract:

Original paper

Serum IL-17A in Behçet’s disease

Nazan Emiroglu

,

Fatma Pelin Cengiz

,

Gul Bahar Erdem

Postep Derm Alergol 2015; XXXII (5): 358–361

DOI: https://doi.org/10.5114/pdia.2015.54745

Online publish date: 2015/10/29

View full text Get citation

Introduction: Behçet’s disease is a chronic multisystem disease with spontaneous remissions and relapses. Several studies show that autoimmune mechanisms play an important role in the development of Behçet’s disease. Activation of T cells and neutrophils is important in the pathogenesis of the disease. Interleukin 17 (IL-17) is a new cytokine that induces several types of cells to secrete proinflammatory cytokines in many inflammatory and autoimmune diseases.

Aim: This study evaluated the serum levels of IL-17A in active and stable Behçet’s disease patients.

Material and methods: Seventy-six patients who had active clinic findings of Behçet’s disease were enrolled in our study. Seventy age- and sex-matched controls were also enrolled. Serum IL-17 levels were studied in peripheral venous blood samples.

Results: No significant differences were found between active Behçet’s disease patients and controls in terms

of serum IL-17A (p > 0.05).

Conclusions: These results suggest that IL-17A serum levels do not play an important role in active Behçet’s disease.

keywords:

Serum IL-17A in Behçet’s disease

Nazan Emiroglu , Fatma Pelin Cengiz , Gul Bahar Erdem

active, Behçet’s disease, interleukin 17

Nazan Emiroglu

,

Fatma Pelin Cengiz

,

Gul Bahar Erdem